Bloomberg (7/26/13) reports that unsealed court documents suggest that Bard’s Davol subsidiary was warned by Chevron Phillips Chemical Co. - maker of the resin-based plastic used in the transvaginal mesh - that the plastic should not be used as a permanent implant in patients. But e-mails sent in 2004 and 2007 suggest executives at Davol encouraged the use of the plastic without telling Chevron Phillips executives that they were doing so.
Lawsuits concerning the Avaulta mesh allege Bard improperly tested its product and did not adequately warn patients about potential risks. They allege patients suffered serious harm, including mesh adhesion to the vaginal walls, requiring multiple surgeries to remove the mesh and repair internal damage. Transvaginal mesh is used to treat stress urinary incontinence and pelvic organ prolapse but can allegedly erode, causing severe pain, internal bleeding and organ damage.
READ MORE BARD AVAULTA TVM LEGAL NEWS
Several claims made in Cisson’s lawsuit have been dismissed, according to The Herald-Dispatch (7/15/13), including claims of manufacturer’s defect.
A California lawsuit against Bard involving the Avaulta Plus implant resulted in an award of $3.6 million.
Bard is not the only transvaginal mesh company to face lawsuits alleging transvaginal mesh was defectively designed. Boston Scientific, Johnson & Johnson and other companies also face similar lawsuits.
The Bard lawsuits are In re C.R. Bard Inc. Pelvic Repair System Products Liability Litigation, 2:10-md-02187, and Cisson v. C.R. Bard Inc., 2:11-cv-00195, U.S. District Court, Southern District of West Virginia (Charleston).